ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In CML, clonal progression with the formation of new mutations in the ABL kinase domain is assumed to develop under the selective pressure of TKI treatment, and patients with chronic-phase CML are very unlikely to harbour resistant mutations at diagnosis.28